Ticagrelor versus clopidogrel in patients with STEMI treated with thrombolysis: the MIRTOS trial.

ABSTRACT:

Aims

We aimed to demonstrate whether coronary microvascular function is improved after ticagrelor administration compared to clopidogrel administration in STEMI subjects undergoing thrombolysis.

Methods and results

MIRTOS is a multicentre study of ticagrelor versus clopidogrel in STEMI subjects treated with fibrinolysis. We enrolled 335 patients <75 years old with STEMI eligible for thrombolysis, of whom 167 were randomised to receive clopidogrel and 168 to receive ticagrelor together with thrombolysis. Primary outcome was the difference in post-PCI corrected TIMI frame count (CTFC). All clinical events were recorded in a three-month follow-up period. From the 335 patients who were randomised, 259 underwent PCI (129 clopidogrel and 130 ticagrelor) and 154 angiographies were

SUBMITTER: Hamilos M 

PROVIDER: S-EPMC9724948 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature